New vessels, new approaches: Angiogenesis as a therapeutic target in musculoskeletal disorders

International Journal of Experimental Pathology

Volumn 80, Issue 5, 1999, Pages 235-250

  Ballara, Sundeept C ^a   Miotla, Jadwiga M ^a   Paleolog, Ewa M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Arthritis; Musculoskeletal disorders; VEGF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; INTERVERTEBRAL DISK; MUSCULOSKELETAL DISEASE; NEOVASCULARIZATION (PATHOLOGY); OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SOFT TISSUE DISEASE; TISSUE REPAIR; VASCULARIZATION;

ARTHRITIS; ENDOTHELIAL GROWTH FACTORS; HUMANS; JOINTS; LYMPHOKINES; MUSCULOSKELETAL DISEASES; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032705201     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2613.1999.00129.x     Document Type: Review

References (85)

1. ACHEN M.G. & STACKER S.A. (1998) The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int. J. Exp. Pathol. 79, 255-265.
2. ASAHARA T., MUROHARA T., SULLIVAN A. ET AL. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
3. ASTROM M. & RAUSING A. (1995) Chronic Achilles tendinopathy. A survey of surgical and histopathologic findings. Clin. Orthop. 316, 151-164.
4. BLAKE D.R., MERRY P., UNSWORTH J. ET AL. (1989) Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1 (8633), 289-293.
5. BREM S. (1998) Angiogenesis antagonists: current clinical trials. Angiogenesis 2, 9-20.
6. BRENNAN F.M., CHANTRY D., JACKSON A., MAINI R. & FELDMANN M. (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (8657), 244-247.
7. BROWN L.F., DETMAR M., CLAFFEY K. ET AL. (1997) Vascular permeability factor/vascular endothelial growth factor: a multi-functional angiogenic cytokine. EXS 79, 233-269.
8. BROWN R.A., WEISS J.B., TOMLINSON I.W., PHILLIPS P. & KUMAR S. (1980) Angiogenic factor from synovial fluid resembling that from tumours. Lancet 1, 682-685.
9. BROWN R.A. & WEISS J.B. (1988) Neovascularisation and its role in the osteoarthritic process. Ann. Rheum. Dis. 47, 881-885.
10. BURGESS W.H. & MACIAG T. (1989) The heparin-binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem. 88, 575-606.
11. CAO R., WU H.L., VEITONMAKI N. ET AL. (1999) Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 96, 5728-5733.
12. CARLEVARO M.F., ALBINI A., RIBATTI D. ET AL. (1997) Transferrin promotes endothelial cell migration and invasion: implication in cartilage neovascularization. J. Cell Biol. 136, 1375-1384.
13. CARR A.J. & NORRIS S.H. (1989) The blood supply of the calcaneal tendon. J. Bone Joint Surg. 71, 100-101.
14. CEPONIS A., KONTTINEN Y.T., IMAI S. ET AL. (1998) Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study. Br. J. Rheumatol. 37, 170-178.
15. CHU C.Q., FIELD M., ALLARD S., ABNEY E., FELDMANN M. & MAINI R.N. (1992) Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 31, 653-661.
16. CLAESSON-WELSH L. (1994) Platelet-derived growth factor receptor signals. J. Biol. Chem. 269, 32023-32026.
17. COLVILLE-NASH P.R. & WILLOUGHBY D.A. (1997) Growth factors in angiogenesis: current interest and therapeutic potential. Mol. Med. Today 3, 14-23.
18. COX D.A. & MAURER T. (1997) Transforming growth factor-beta. Clin. Immunol. Immunopathol. 83, 25-30.
19. DECKER J.L. (1983) American Rheumatism Association nomenclature and classification of arthritis and rheumatism (1983). Arthritis Rheum. 26, 1029-1032.
20. DETERME D., RONGIERES M., KANY J. ET AL. (1996) Anatomic study of the tendinous rotator cuff of the shoulder. Surg. Radiol. Anat. 18, 195-200.
21. EISENSTEIN R., KUETTNER K.E., NEAPOLITAN C., SOBLE L.W. & SORGENTE N. (1975) The resistance of certain tissues to invasion. III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture. Am. J. Pathol. 81, 337-347.
22. ELLIOTT M.J., MAINI R.N., FELDMANN M. ET AL. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110.
23. FAVA R.A., OLSEN N.J., SPENCER-GREEN G. ET AL. (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180, 341-346.
24. FELDMANN M., BRENNAN F.M. & MAINI R.N. (1996) Rheumatoid arthritis. Cell 85, 307-310.
25. FOLKMAN J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
26. GERBER H.P., VU T.H., RYAN A.M., KOWALSKI J., WERB Z. & FERRARA N. (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623-628.
27. GRAF J., NEUSEL E., FREESE U., SIMANK H.G. & NIETHARD F.U. (1992) Subchondral vascularisation and osteoarthritis. Int. Orthop. 16, 113-117.
28. HARADA M., MITSUYAMA K., YOSHIDA H. ET AL. (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 27, 377-380.
29. HARRIS A.L. (1998) Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res. 152, 341-352.
30. HIRAKI Y., MITSUI K., ENDO N. ET AL. (1999) Molecular cloning of human chondromodulin-I, a cartilage-derived growth modulating factor, and its expression in Chinese hamster ovary cells. Eur J. Biochem. 260, 869-878.
31. HOSAKA S., SHAH M.R., BARQUIN N., HAINES G.K. & KOCH A.E. (1995) Expression of basic fibroblast growth factor and angiogenin in arthritis. Pathobiology 63, 249-256.
32. JACKSON J.R., MINTON J.A., HO M.L., WEI N. & WINKLER J.D. (1997) Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J. Rheumatol. 24, 1253-1259.
33. JONES P.B., MAKKI R.J. & WEISS J.B. (1994) Endothelial cell stimulating angiogenesis factor - a new biological marker for disease activity in ankylosing spondylitis? Br. J. Rheumatol. 33, 332-335.
34. JOSEFSSON E. & TARKOWSKI A. (1997) Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum. 40, 154-163.
35. KAUPPILA L.I. (1995) Ingrowth of blood vessels in disc degeneration. Angiographic and histological studies of cadaveric spines. J. Bone Joint Surg. Am. 77, 26-31.
36. KIAER T., GRONLUND J. & SORENSEN K.H. (1988) Subchondral pO2, pCO2, pressure, pH, and lactate in human osteoarthritis of the hip. Clin. Orthop. 229, 149-155.
37. KING T.V. & VALLEE B.L. (1991) Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits. J. Bone Joint Surg. 73, 587-590.
38. KOCH A.E., HARLOW L.A., HAINES G.K. et al. (1994) Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149-4156.
39. KVIST M., HURME T., KANNUS P. ET AL. (1995) Vascular density at the myotendinous junction of the rat gastrocnemius muscle after immobilization and remobilization. Am. J. Sports Med. 23, 359-364.
40. LAWRENCE R.C., HOCHBERG M.C., KELSEY J.L. ET AL. (1989) Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J. Rheumatol. 16, 427-441.
41. LOSORDO D.W., VALE P.R., SYMES J.F. ET AL. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF 165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804.
42. LYNCH C.N., WANG Y.C., LUND J.K., CHEN Y.W., LEAL J.A. & WILEY S.R. (1999) TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem. 274, 8455-8459.
43. MAROUDAS A., STOCKWELL R.A., NACHEMSON A. & URBAN J. (1975) Factors involved in the nutrition of the human lumbar intervertebral disc: cellularity and diffusion of glucose in vitro. J. Anat. 120, 113-130.
44. McFARLAND C.D., BROWN R.A., McLAUGHLIN B., ALI S.Y. & WEISS J.B. (1990) Production of endothelial cell stimulating angiogenesis factor (ESAF) by chondrocytes during in vitro cartilage calcification. Bone Miner. 11, 319-333.
45. McLAUGHLIN B. & WEISS J.B. (1996) Endothelial-cell-stimulating angiogenesis factor (ESAF) activates progelatinase A (72 kDa type IV collagenase), prostromelysin 1 and procollagenase and reactivates their complexes with tissue inhibitors of metalloproteinases: a role for ESAF in non-inflammatory angiogenesis. Biochem. J. 317, 739-745.
46. MORELAND L.W., BAUMGARTNER S.W., SCHIFF M.H. ET AL. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein. N. Engl. J. Med. 337, 141-147.
47. MORELAND L.W., SCHIFF M.H., BAUMGARTNER S.W. ET AL. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478-486.
48. MORI S., YOSHIKAWA H., HASHIMOTO J. ET AL. (1998) Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone 22, 99-105.
49. MOSES M.A., SUDHALTER J. & LANGER R. (1990) Identification of an inhibitor of neovascularization from cartilage. Science 248, 1408-1410.
50. MOSES M.A., WIEDERSCHAIN D., WU I. ET AL. (1999) Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. USA 96, 2645-2650.
51. NAGASHIMA M., YOSHINO S., ISHIWATA T. & ASANO G. (1995) Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J. Rheumatol. 22, 1624-1630.
52. NEUFELD G., COHEN T., GENGRINOVITCH S. & POLTORAK Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22.
53. ODEDRA R. & WEISS J.B. (1991) Low molecular weight angiogenesis factors. Pharmacol. Ther. 49, 111-124.
54. OLIVER S.J., BANQUERIGO M.L. & BRAHN E. (1994) Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol. 157, 291-299.
55. OLIVER S.J., CHENG T.P., BANQUERIGO M.L. & BRAHN E. (1995) Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol. 166, 196-206.
56. OLIVER S.J., CHENG T.P., BANQUERIGO M.L. & BRAHN E. (1998) The effect of thalidomide and 2 analogs on collagen induced arthritis. J. Rheumatol. 25, 964-969.
57. O'REILLY M.S., BOEHM T., SHING Y. ET AL. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
58. PALEOLOG E.M. (1996) Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br. J. Rheumatol. 35, 917-919.
59. PALEOLOG E.M., HUNT M., ELLIOTT M.J., FELDMANN M., MAINI R.N. & WOODY J.N. (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 39, 1082-1091.
60. PALEOLOG E.M. & FAVA R.A. (1998) Angiogenesis in rheumatoid arthritis. Implications for Future Therapeutic Strategies. Springer Seminars in Immunopathology 20, 73-94.
61. PALEOLOG E.M. & MIOTLA J.M. (1998) Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 2, 295-307.
62. PALEOLOG E.M., YOUNG S., STARK A.C., McCLOSKEY R.V., FELDMANN M. & MAINI R.N. (1998) Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum. 41, 1258-1265.
63. PEACOCK D.J., BANQUERIGO M.L. & BRAHN E. (1992) Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. 175, 1135-1138.
64. QU Z., HUANG X.N., AHMADI P. ET AL. (1995) Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab. Invest. 73, 339-346.
65. REMMERS E.F., SANO H., LAFYATIS R. ET AL. (1991) Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J. Rheumatol. 18, 7-13.
66. RODEO S.A., HANNAFIN J.A., TOM J., WARREN R.F. & WICKIEWICZ T.L. (1997) Immunolocalization of cytokines and their receptors in adhesive capsulitis of the shoulder. J. Orthop. Res. 15, 427-436.
67. ROONEY M., CONDELL D., QUINLAN W. ET AL. (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 31, 956-963.
68. ROSEN E.M. & GOLDBERG I.D. (1997) Regulation of angiogenesis by scatter factor. EXS 79, 193-208.
69. RYUTO M., ONO M., IZUMI H. ET AL. (1996) Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271, 28220-28228.
70. SANO H., FOROUGH R., MAIER J.A. ET AL. (1990) Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J. Cell Biol. 110, 1417-1426.
71. SANO H., ENGLEKA K., MATHERN P. ET AL. (1993) Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J. Clin. Invest. 91, 553-565.
72. SEMBLE E.L., TURNER R.A. & McCRICKARD E.L. (1985) Rheumatoid arthritis and osteoarthritis synovial fluid effects on primary human endothelial cell cultures. J. Rheumatol. 12, 237-241.
73. SHEU J.R., FU C.C., TSAI M.L. & CHUNG W.J. (1998) Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res. 18, 4435-4441.
74. SHWEIKI D., ITIN A., SOFFER D. & KESHET E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
75. STEPHENS R.W., GHOSH P. & TAYLOR T.K. (1979) The pathogenesis of osteoarthrosis. Med. Hypotheses 5, 809-816.
76. STEVENS C.R., BLAKE D.R., MERRY P., REVELL P.A. & LEVICK J.R. (1991a) A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum. 34, 1508-1513.
77. STEVENS C.R., WILLIAMS R.B., FARRELL A.J. & BLAKE D.R. (1991b) Hypoxia and inflammatory synovitis: observations and speculation. Ann. Rheum. Dis. 50, 124-132.
78. STORGARD C.M., STUPACK D.G., JONCZYK A., GOODMAN S.L., FOX R.I. & CHERESH D.A. (1999) Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest. 103, 47-54.
79. SYMMONS D.P., JONES M.A., SCOTT D.L. & PRIOR P. (1998) Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J. Rheumatol. 25, 1072-1077.
80. TOLONEN J., GRONBLAD M., VIRRI J. ET AL. (1997) Platelet-derived growth factor and vascular endothelial growth factor expression in disc herniation tissue: an immunohistochemical study. Eur. Spine J. 6, 63-69.
81. WALSH D.A., WADE M., MAPP P.I. & BLAKE D.R. (1998) Focally regulated endothelial proliferation and cell death in human synovium. Am. J. Pathol. 152, 691-702.
82. WANG D.S., YAMAZAKI K., NOHTOMI K. ET AL. (1996) Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J. Bone Miner. Res. 11, 472-479.
83. WESTACOTT C.I. & SHARIF M. (1996) Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin. Arthritis Rheum. 25, 254-272.
84. YOSHIDA S., ONO M., SHONO T. ET AL. (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell Biol. 17, 4015-4023.
85. ZHAI Y., NI J., JIANG G.W. ET AL. (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 13, 181-189.